These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 3553348)
21. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. Stürenburg E; Kühn A; Mack D; Laufs R J Antimicrob Chemother; 2004 Aug; 54(2):406-9. PubMed ID: 15201232 [TBL] [Abstract][Full Text] [Related]
22. In vitro selection and characterization of mutants in TEM-1-producing Escherichia coli by ceftazidime and ceftibuten. Perilli M; Segatore B; Tavio M; Setacci D; Celenza G; De Santis F; Pellegrini C; Rossolini GM; Amicosante G J Chemother; 2007 Apr; 19(2):123-6. PubMed ID: 17434819 [TBL] [Abstract][Full Text] [Related]
23. CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection. Robin F; Delmas J; Archambaud M; Schweitzer C; Chanal C; Bonnet R Antimicrob Agents Chemother; 2006 Jul; 50(7):2403-8. PubMed ID: 16801418 [TBL] [Abstract][Full Text] [Related]
24. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. Oteo J; Navarro C; Cercenado E; Delgado-Iribarren A; Wilhelmi I; Orden B; García C; Miguelañez S; Pérez-Vázquez M; García-Cobos S; Aracil B; Bautista V; Campos J J Clin Microbiol; 2006 Jul; 44(7):2359-66. PubMed ID: 16825350 [TBL] [Abstract][Full Text] [Related]
25. [A novel extended-spectrum beta-lactamase in a ceftazidime-resistant isolate of E. coli]. Cheng Y; Li Y; Chen M Wei Sheng Wu Xue Bao; 1994 Oct; 34(5):360-6. PubMed ID: 7871780 [TBL] [Abstract][Full Text] [Related]
26. TRC-1: emergence of a clavulanic acid-resistant TEM beta-lactamase in a clinical strain. Thomson CJ; Amyes SG FEMS Microbiol Lett; 1992 Mar; 70(2):113-7. PubMed ID: 1316862 [TBL] [Abstract][Full Text] [Related]
28. [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital]. Bémer-Melchior P; Gilly L; Jugroot-Klotz K; Brun T; Névot P; Paul G Pathol Biol (Paris); 1995 Nov; 43(9):760-5. PubMed ID: 8746097 [TBL] [Abstract][Full Text] [Related]
29. Amoxycillin/clavulanate resistant Escherichia coli. Williams H; King A; Shannon K; Phillips I Lancet; 1988 Feb; 1(8580):304-5. PubMed ID: 2893121 [No Abstract] [Full Text] [Related]
30. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635 [TBL] [Abstract][Full Text] [Related]
31. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin . Livermore DM; Seetulsingh P J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013 [TBL] [Abstract][Full Text] [Related]
32. TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. Robin F; Delmas J; Brebion A; Dubois D; Constantin JM; Bonnet R Antimicrob Agents Chemother; 2007 Nov; 51(11):4181-3. PubMed ID: 17709463 [TBL] [Abstract][Full Text] [Related]
33. Mutants of the TEM-1 beta-lactamase conferring resistance to ceftazidime. Payne DJ; Marriott MS; Amyes SG J Antimicrob Chemother; 1989 Aug; 24(2):103-10. PubMed ID: 2676935 [TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases. Bowker KE; Noel AR; Walsh TR; Rogers CA; MacGowan AP Antimicrob Agents Chemother; 2004 Nov; 48(11):4482-4. PubMed ID: 15504890 [TBL] [Abstract][Full Text] [Related]
35. Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. Seetulsingh PS; Hall LM; Livermore DM J Antimicrob Chemother; 1991 Jun; 27(6):749-59. PubMed ID: 1938685 [TBL] [Abstract][Full Text] [Related]
36. Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins. Bauernfeind A; Hörl G Infection; 1987; 15(4):257-9. PubMed ID: 3312022 [TBL] [Abstract][Full Text] [Related]
37. [Appearance of Escherichia coli strain with high production of cephalosporinase during treatment with an amoxicillin and clavulanic acid combination]. Aubert G; Peyle V; Dumont N; el Fassi M; Dorche G Ann Biol Clin (Paris); 1990; 48(7):449-54. PubMed ID: 2278408 [TBL] [Abstract][Full Text] [Related]
38. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer. London N; Thomson CJ; Amyes SG; Stobberingh E FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670 [TBL] [Abstract][Full Text] [Related]
39. Resistance to the third-generation cephalosporin ceftazidime by a deacylation-deficient mutant of the TEM β-lactamase by the uncommon covalent-trapping mechanism. Antunes NT; Frase H; Toth M; Mobashery S; Vakulenko SB Biochemistry; 2011 Jul; 50(29):6387-95. PubMed ID: 21696166 [TBL] [Abstract][Full Text] [Related]
40. Novel SHV-derived extended-spectrum beta-lactamase, SHV-57, that confers resistance to ceftazidime but not cefazolin. Ma L; Alba J; Chang FY; Ishiguro M; Yamaguchi K; Siu LK; Ishii Y Antimicrob Agents Chemother; 2005 Feb; 49(2):600-5. PubMed ID: 15673739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]